Los Angeles Capital Management
TARS icon

Los Angeles Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Los Angeles Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.82M Sell
25,881
-5,612
-18% -$392K 0.01% 526
2025
Q4 		$2.17M Sell
31,493
-5,609
-15% -$419K 0.01% 430
2025
Q3 		$2.2M Buy
37,102
+13,569
+58% +$668K 0.01% 479
2025
Q2 		$953K Buy
+23,533
New +$1.06M ﹤0.01% 652

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Los Angeles Capital Management's TARS Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Tarsus Pharmaceuticals (TARS) stake by 18% in Q1 2026, selling an estimated $392K and leaving 25,881 shares worth $1.82M. The position accounts for 0.01% of the portfolio, ranked #526.

Los Angeles Capital Management first reported a position in TARS in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.2M in Q3 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Los Angeles Capital Management held 25,881 shares of Tarsus Pharmaceuticals worth $1.82M as of Q1 2026.
  • Los Angeles Capital Management sold 5,612 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $392K.
  • Tarsus Pharmaceuticals made up 0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #526 holding.
  • Los Angeles Capital Management first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Los Angeles Capital Management's Tarsus Pharmaceuticals position peaked at $2.2M in Q3 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.